Autopsy report · NCT02826512

A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients

Cause of deathSlow enrollment Automatic label, confidence 0.5, unverified. How labels are made.

“Not enough eligble patient can be found, too many screen failures”

The sponsor’s own words in the registry.

Life of this trial

Registered 1 year 10 months before it started.
Ran for about 4 years 2 months before it stopped.
9 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: The Netherlands Cancer Institute
Sponsor type: University, hospital or other
Conditions: Breast Cancer
Interventions: Niraparib
Participants: 9
Sites: 3
Countries: Netherlands

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.